Skip to main content

  • Home
  • About Us
    • Company Summary
    • Senior Management
    • The Board
    • Corporate Governance
      • Board Charter
      • Audit & Risk
      • Remuneration & Nominations
      • Code of Conduct
      • Continuous Disclosure
      • Risk Management
      • Shareholder Communication
      • Securities Trading
      • Board & Executive Evaluation
      • Diversity
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Sygenus
  • Product Pipeline
    • Pipeline Overview
    • Human Health
      • Progenza
      • Human Cancer Vaccine
      • Sygenus
    • Animal Health
      • CryoShot Canine
      • Kvax
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  • Home
  • About Us
    • Company Summary
    • Senior Management
    • The Board
    • Corporate Governance
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Sygenus
  • Product Pipeline
    • Pipeline Overview
    • Human Health
    • Animal Health
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  1. Home
  2. News
  3. News archive

News archive - 2017

  • Monday, 11 December 2017

    Regeneus appoints Japan-based non-executive director with extensive pharmaceutical industry experience

    See full story
  • Thursday, 2 November 2017

    CEO Presentation to 2017 Annual General Meeting - Highlights and Business Update for FY17

    See full story
  • Wednesday, 1 November 2017

    Presentation on Japan First Strategy at Ord Minnett

    See full story
  • Monday, 9 October 2017

    Regeneus to attend BioJapan in partnership with AGC

    Australian Financial Review Article

    See full story
  • Tuesday, 26 September 2017

    AGC to Expand Production Capacity at Its Subsidiary CMC Biologics Copenhagen, Denmark Facility

    The strategic expansion aims to meet the increasing demand for antibody drug development and production

    See full story
  • Friday, 25 August 2017

    Regeneus Ltd (ASX: RGS) ABN Interview with John Martin on Progenza and the Platform Technology

    See full story
  • More
© 2020 Regeneus Ltd | Privacy | Terms of Service